Equities analysts expect G1 THERAPEUTICS (NASDAQ:GTHX) to report earnings of ($0.68) per share for the current quarter, according to Zacks. Zero analysts have made estimates for G1 THERAPEUTICS’s earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.45). The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that G1 THERAPEUTICS will report full year earnings of ($2.19) per share for the current year. For the next year, analysts expect that the business will post earnings of ($2.36) per share, with EPS estimates ranging from ($2.41) to ($2.31). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for G1 THERAPEUTICS.

A number of research firms recently commented on GTHX. Cowen and Company assumed coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They issued an “outperform” rating and a $31.00 price target for the company. Needham & Company LLC assumed coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 target price for the company. Wedbush assumed coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 target price for the company. Finally, J P Morgan Chase & Co assumed coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 target price for the company.

In other G1 THERAPEUTICS news, insider Ra Capital Healthcare Fund Lp bought 400,000 shares of the stock in a transaction on Monday, May 22nd. The stock was purchased at an average price of $15.00 per share, with a total value of $6,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Clay Thorp bought 133,333 shares of the stock in a transaction on Monday, May 22nd. The shares were acquired at an average cost of $15.00 per share, with a total value of $1,999,995.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 833,333 shares of company stock valued at $12,499,995.

WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/06/zacks-analysts-anticipate-g1-therapeutics-gthx-will-announce-earnings-of-0-68-per-share.html.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) traded down 1.11% during trading on Thursday, hitting $16.93. 14,367 shares of the stock were exchanged. G1 THERAPEUTICS has a 1-year low of $13.35 and a 1-year high of $20.60. The firm’s 50-day moving average is $17.50 and its 200 day moving average is $17.50. The company’s market cap is $477.34 million.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Get a free copy of the Zacks research report on G1 THERAPEUTICS (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.